XORTX Therapeutics Statistics
Total Valuation
XRTX has a market cap or net worth of $3.25 million. The enterprise value is $2.43 million.
Important Dates
The last earnings date was Friday, February 27, 2026, before market open.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XRTX has 6.96 million shares outstanding. The number of shares has increased by 64.48% in one year.
| Current Share Class | 6.96M |
| Shares Outstanding | 6.96M |
| Shares Change (YoY) | +64.48% |
| Shares Change (QoQ) | +34.76% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 5.87% |
| Float | 6.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.11 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.00% and return on invested capital (ROIC) is -57.75%.
| Return on Equity (ROE) | -98.00% |
| Return on Assets (ROA) | -46.84% |
| Return on Invested Capital (ROIC) | -57.75% |
| Return on Capital Employed (ROCE) | -121.85% |
| Weighted Average Cost of Capital (WACC) | 4.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$885,435 |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.89% in the last 52 weeks. The beta is 0.10, so XRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -60.89% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.69 |
| Relative Strength Index (RSI) | 41.01 |
| Average Volume (20 Days) | 45,145 |
Short Selling Information
The latest short interest is 144,276, so 2.07% of the outstanding shares have been sold short.
| Short Interest | 144,276 |
| Short Previous Month | 107,400 |
| Short % of Shares Out | 2.07% |
| Short % of Float | 2.31% |
| Short Ratio (days to cover) | 0.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.54M |
| Pretax Income | -2.66M |
| Net Income | -2.66M |
| EBITDA | -2.51M |
| EBIT | -2.54M |
| Earnings Per Share (EPS) | -$0.56 |
Full Income StatementBalance Sheet
The company has $864,514 in cash and $37,287 in debt, with a net cash position of $827,227 or $0.12 per share.
| Cash & Cash Equivalents | 864,514 |
| Total Debt | 37,287 |
| Net Cash | 827,227 |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 2.08M |
| Book Value Per Share | 0.30 |
| Working Capital | 662,027 |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.77M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 31,352 |
| Net Borrowing | -89,572 |
| Free Cash Flow | -2.77M |
| FCF Per Share | -$0.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
